Pharma Weekly: Can Cancer Drug Cuts Save Patients 3,540 Cr?

Cancer drug price reductions could ease treatment expenses, while the government's proposed Rs 7,000 crore bulk drug Production Linked Incentive (PLI) scheme aims to strengthen domestic manufacturing.

Meanwhile, proposed changes to clinical trial regulations could attract multinational pharmaceutical companies to conduct early-stage research in India.

These developments connect three important priorities for the sector: affordable medicines, stronger manufacturing capabilities and greater participation in global drug innovation. Together, they could shape India's next phase of pharmaceutical growth.

1. Cancer Drug Price Cuts and Bulk Drug PLI Could Strengthen India's Pharma Sector

The revised maximum retail prices (MRPs) of 1,364 anti-cancer formulations took effect on November 9, 2026. The government expects these reductions to generate annual consumer savings of Rs 3,540.38 crore.

The National Pharmaceutical Pricing Authority (NPPA) also capped trade margins on 137 anti-cancer medicines. Key developments include:

• 679 brands recorded price reductions exceeding 50 percent.
• The steepest price reduction reached 96.45 percent.
• Regular price monitoring will remain important to protect patients from excessive mark-ups and maintain affordability.

Beyond price regulation, the proposed Rs 7,000 crore bulk drug PLI scheme aims to address domestic manufacturing gaps. Its proposed allocation includes:

• Rs 5,000 crore for production incentives.
• Rs 2,000 crore for research, infrastructure and capital subsidies.

Also Read: Moving Indian Pharma from Volume to Value Through Innovation and Strategic Partnerships

2. Clinical Trial Reforms Could Expand India's Global Pharma Role

The government is considering allowing multinational pharmaceutical companies to conduct first-in-human Phase I clinical trials in India, including studies of molecules discovered overseas. Currently, regulations generally require foreign-developed drugs to generate overseas Phase I data before companies seek further trials in India.

The proposed change could:

• Bring India into earlier stages of global drug development.
• Attract multinational pharmaceutical companies and research investments.
• Create more opportunities for Indian research institutions to participate in innovative drug development.

However, regulators must maintain strong safeguards, including informed consent, independent ethics committee approvals, and compensation for trial-related injuries.

Greater research participation, stronger domestic manufacturing, and affordable cancer drug access could help India build a more competitive pharmaceutical ecosystem. The industry must also ensure that price regulation delivers lasting benefits for patients.